Kyverna Therapeutics (KYTX) EPS (Basic) (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of EPS (Basic) data on file, last reported at -$1.23 in Q1 2026.

• Quarterly EPS (Basic) fell 16.44% year-over-year to -$1.23 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.46 (up 12.43% YoY) and the FY2025 annual result came in at -$4.62, down 35.95% from the prior year.
• EPS (Basic) eased to -$1.23 in Q1 2026, from -$0.85 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of -$0.85 in Q4 2025 to a low of -$30.63 in Q4 2023.
• A 4-year average of -$7.59 and a median of -$1.2 in 2024 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2024 — EPS (Basic) surged 96.56% — and 2025, when it decreased 21.37%.
• Tracing KYTX's EPS (Basic) over 4 years: stood at -$30.63 in 2023, then surged by 96.56% to -$1.05 in 2024, then rose by 19.16% to -$0.85 in 2025, then tumbled by 43.95% to -$1.23 in 2026.
• The last three EPS (Basic) figures came in at -$1.23 (Q1 2026), -$0.85 (Q4 2025), and -$1.22 (Q3 2025), per Business Quant data.